Lichen Nitidus

2018-04-24 14:36:53

Market Overview
According to a new report published by Reports Monitor titled, “Lichen Nitidus Market by Treatment, and End-User: Global Opportunity Analysis and Industry Forecast, 2017–2025,” the lichen nitidus market was valued at XX million in 2016, and is projected to reach at XX million by 2025, growing at a CAGR of XX% from 2017 to 2025. 

Lichen nitidus is a chronic inflammation related to skin with unknown causative agent. Lichen nitidus appears as clusters of tiny, papules and vary in size, shape and colour. Lichen nitidus bumps commonly occur on the chest, abdomen, arms and genital areas and rarely on palms, fingernails or soles of the feet. Inflammation in skin cells gives rise to lichen nitidus where in T lymphocytes get activating resulting into formation of micropapules. Risk factor includes association with other disease such as lichen planus, eczema, tuberculosis, crohn’s disease and juvenile rheumatoid arthritis.  It does not cause irritation and gets clear up on its own without treatment. 

Request a Sample Copy @

Rising number of skin disorders across the globe is the vital aspect leading the growth of the lichen nitidus market. Additionally, advancement in healthcare sectors further drives the growth of the market. However, less awareness among population and ability of the condition to heal on its own might restrict the growth of the market. North America lichen nitidus market is affected owing to well-developed healthcare infrastructure, large population affected with the skin diseases, demand for advanced treatment option and high expenditure on healthcare facilities.

The global lichen nitidus treatment market is segmented on the basis of treatment and end-user. In terms of treatment, the market is divided into corticosteroids, antihistamines, retinoid phototherapy and other treatment. Based on end user, the market is categorized into hospitals, dermatology clinics, and others.
Competitive Landscape

Players operating in the market are AstraZeneca, Pfizer Inc., Merck Sharp & Dohme Corp, Hubei Gedian Humanwell Pharmaceutical Co., Ltd, Novartis AG, GlaxoSmithKline plc., Sanofi, Farmabios SPA and Horizon Pharma plc.
About Garner Insights:

We at Garner provide a comprehensive analysis by providing in-depth reports of the various market verticals. Our Mission is to provide a detailed analysis of the vast markets worldwide backed by rich data. Decision makers can now rely on our well-defined data gathering methods to get the correct and accurate market forecasting along with detailed analysis.

Contact Us:

Kevin Thomas


+1 513 549 5911 (US)

+44 203 318 2846 (UK)

Email: [email protected] 

Related Press Releases